Interplay between expanded endocannabinoid (eCB) system and inflamm-aging: Implication for accelerated atherosclerosis in people living with HIV (PLWH) under ARTLearn More
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized studyLearn More
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIVLearn More
A proof-of-concept study to assess the effect of recombinant human growth hormone on the size of the replication-competent viral reservoir in HIV-infected individuals on suppressive ARTLearn More
Predictive value of inflammatory biomarkers in untreated HIV disease progression, and their response to initiation of antiretroviral therapyLearn More
Chloroquine as a modulator of T cell immune activation to improve CD4 recovery in HIV-infected participants receiving antiretroviral therapy: A proof-of-concept studyLearn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.